Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Vir Biotechnology ( (VIR) ) is now available.
On January 24, 2025, Vir Biotechnology announced the departure of their Executive Vice President and Chief Technology Officer, Ann (Aine) M. Hanly, Ph.D., effective February 26, 2025. The company appointed Maninder Hora, Ph.D. as her successor, effective February 27, 2025, which indicates a strategic shift in leadership that could impact the company’s operational dynamics and stakeholder confidence.
More about Vir Biotechnology
Vir Biotechnology operates in the biotechnology industry, focusing on the development of products and services aimed at combating infectious diseases.
YTD Price Performance: 49.93%
Average Trading Volume: 2,250,265
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.46B
For an in-depth examination of VIR stock, go to TipRanks’ Stock Analysis page.
